Q-omics provides the consensus-scored MIR3667 profile across patient tissues and cancer cell-line models. MIR3667 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR3667 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR3667 RNA expression shows 6,529 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, BRCA, and TGCT as cancer lineages where MIR3667 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3667 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3667 survival associations across molecular data types. MIR3667 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3667 RNA expression–survival associations across cancer types. High MIR3667 expression shows unfavorable associations in HNSC, KIRC, ESCA, KIRP and UVM, but favorable associations in DLBC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .019). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR3667 RNA expression.
This table summarizes MIR3667 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3667. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3667 shows lower tumor expression in BRCA. The BRCA box plot shows higher MIR3667 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p = .045).
This table shows molecular features associated with MIR3667 in patient tissues and cancer cell lines. In patient samples, MIR3667 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
